Trophogen has developed a comprehensive platform technology that focuses on creating patented long-acting superagonist analogs of glycoprotein hormones and growth factors for both human and animal applications. This innovative approach aims to produce highly potent and effective products that are also safe and non-immunogenic. The company’s lead products include recombinant analogs of Follicle-Stimulating Hormone (FSH), Thyroid-Stimulating Hormone (TSH), and Vascular Endothelial Growth Factor (VEGF), which are fully developed and poised for Investigational New Drug (IND) applications and clinical trials. Trophogen's BioSuperior platform is designed to surpass existing BioBetters and BioSimilars in the imaging, diagnostic, and therapeutic markets, addressing significant needs in areas such as infertility, elective egg banking, and aggressive cancers.

In addition to its human products, Trophogen has also made strides in veterinary medicine, exemplified by its exclusive licensing agreement with Zoetis, Inc. for a recombinant long-acting bovine FSH analog aimed at enhancing superovulation in cattle. The company’s technology leverages advancements in recombinant protein design, which have evolved significantly since the early 1980s, to create superactive analogs that demonstrate substantial increases in bioactivity compared to traditional protein ligands. This positions Trophogen at the forefront of biopharmaceutical innovation, with a robust pipeline of products that cater to both human and animal health markets.

United States

Trophogen, Inc. is a biotechnology company founded in 2001 with series A funding from Toucan Capital, focusing on the development of high affinity glycoprotein hormone and related growth factor analogs for human and animal infertility as well as targeted therapy and imaging of thyroid, ovarian, breast, prostate and testicular cancers.

Trophogen

Company Details